SC 13G | 2023-03-17 | Beryl Capital Management LLC | F-star Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2023-02-14 | Ridgeback Capital Investments L.P. | F-star Therapeutics, Inc. | 52,509 | 0.2% | EDGAR |
SC 13G/A | 2023-02-14 | Ridgeback Capital Investments L.P. | F-star Therapeutics, Inc. | 52,509 | 0.2% | EDGAR |
SC 13G/A | 2022-02-15 | Rock Springs Capital Management LP | F-star Therapeutics, Inc. | 751,889 | 3.6% | EDGAR |
SC 13G/A | 2022-02-14 | Point72 Asset Management, L.P. | F-star Therapeutics, Inc. | 981,249 | 4.8% | EDGAR |
SC 13G/A | 2022-02-14 | Ridgeback Capital Investments L.P. | F-star Therapeutics, Inc. | 1,834,360 | 8.9% | EDGAR |
SC 13G/A | 2022-02-14 | Boxer Capital, LLC | F-star Therapeutics, Inc. | - | 0.0% | EDGAR |
SC 13G/A | 2022-02-14 | Atlas Venture Opportunity Fund I, L.P. | F-star Therapeutics, Inc. | 599,524 | 2.9% | EDGAR |
SC 13G/A | 2022-02-10 | GLAXOSMITHKLINE PLC | F-star Therapeutics, Inc. | 802,627 | 3.9% | EDGAR |
SC 13G/A | 2022-02-08 | Merck KGaA | F-star Therapeutics, Inc. | 75,140 | 0.1% | EDGAR |
SC 13D/A | 2021-05-26 | Cooperatieve AESCAP Venture I U.A. | F-star Therapeutics, Inc. | 615,643 | 3.1% | EDGAR |
SC 13G | 2021-05-18 | Point72 Asset Management, L.P. | F-star Therapeutics, Inc. | 1,100,000 | 5.7% | EDGAR |
SC 13G | 2021-05-17 | Rock Springs Capital Management LP | F-star Therapeutics, Inc. | 1,054,232 | 5.7% | EDGAR |
SC 13G | 2021-05-17 | Boxer Capital, LLC | F-star Therapeutics, Inc. | 1,501,428 | 8.2% | EDGAR |
SC 13G/A | 2021-04-09 | Ridgeback Capital Investments L.P. | F-star Therapeutics, Inc. | 494,360 | 5.4% | EDGAR |
SC 13G/A | 2021-02-16 | BIOTECHNOLOGY VALUE FUND L P | F-star Therapeutics, Inc. | 13,666 | - | EDGAR |
SC 13G/A | 2021-02-16 | Ridgeback Capital Investments L.P. | F-star Therapeutics, Inc. | 407,567 | 4.5% | EDGAR |
SC 13G | 2021-02-03 | Atlas Venture Opportunity Fund I, L.P. | F-star Therapeutics, Inc. | 599,524 | 6.6% | EDGAR |
SC 13G | 2021-02-03 | Atlas Venture Fund VII L P | F-star Therapeutics, Inc. | 574,996 | 6.3% | EDGAR |
SC 13G | 2021-02-01 | Merck KGaA | F-star Therapeutics, Inc. | 493,710 | 5.4% | EDGAR |